Global IgG4-Related Disease Market is segmented By Drug Class (Corticosteroids, Biologics, Immunosuppressants, Antimetabolites, Others) By Disease Type (Type 1 (IgG4-Related) Autoimmune Pancreatitis (AIP), Retroperitoneal IgG4-Related Tubulointerstitial Nephritis (TIN), IgG4-Related Tubulointerstitial Nephritis (TIN), Other IgG4-Related Disorders) By Route of Administration (Injectable, Oral, Other) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The Global IgG4-Related disease market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2024-2031.
IgG4-related disease (IgG4-RD) is an immune-mediated disorder, indicating that it interests the occurrence of disorder in organs as the consequence of an abnormally regulated immune system. IgG4-related disorder is a fibro-inflammatory state that can impact almost any organ system.
Market Scope
|
Metrics |
Details |
|
CAGR |
YY% |
|
Market Size Available for Years |
2022-2031 |
|
Estimation Forecast Period |
2024-2031 |
|
Revenue Units |
Value (US$ Mn) |
|
Segments Covered |
Drug Class, Disease Type, Route of Administration, Distribution Channel |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Largest Region |
North America |
|
Fastest Growing Region |
Asia-Pacific |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
Increasing Market Developments
The increasing market developments are expected to boost the global market during the forecast period. For instance, in September 2023, Zenas BioPharma, a multinational biopharmaceutical corporation dedicated to evolving as a leader in the development and commercialization of immunology-based treatments, formed a license and partnership deal with Bristol Myers Squibb Company to design and commercialize obexelimab for autoimmune disorders in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia.
Moreover, in November 2022, Zenas BioPharma secured a $118 million series B to skyrocket in on a pipeline of immune-based treatments and establish a phase 3 for its top nominee that was approved by Xencor the previous year. Additionally, the increase in product awareness, technological advancements, and increasing research activities with investments and funding are among the additional factors boosting the global market growth during the forecast period.
Stringent Regulatory Authorities
The stringent regulatory authorities authorizing the new drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.
Segment Analysis
The global IgG4-related disease market is segmented based on drug class, disease type, route of administration, distribution channel and region.
Biologics Drug Class is Expected to Dominate Market
Owing to the increase in the research activities for developing distinct biologics treatment options the biologics drug class segment is expected to dominate the global market during the forecast period. For instance, according to clinicaltrials.gov, presently a Phase 3 randomized, double-blind, multicenter, placebo-controlled assessment of Inebilizumab efficacy and safety in IgG4-related disease clinical trial is active and sponsored by the Viela Bio (acquired by Horizon Therapeutics) which is estimated to be completed by 2028.
Further, in January 2023, Zenas BioPharma, a multinational biopharmaceutical corporation dedicated to evolving as a top player in the expansion and commercialization of immune-based treatments dosed the first patient in the INDIGO Phase 3 registrational investigation of obexelimab.
Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the presence of key market players holding the majority of market share through performing distinct market tactics ensures the dominance of North America over the global market during the forecast period. For instance, in December 2022, Amgen a United States-based biopharmaceutical corporation acquired Horizon Therapeutics for about $27.8 billion, intended to replenish Amgen’s rare autoimmune, and inflammatory disorder portfolios as its top-selling drug starts to lose patent exclusivity in the forthcoming year. Further, according to the clinicaltrials.gov presently there are two phase 2 and one phase 3 clinical trials are recruiting while one phase 2 and one phase 3 clinical trial is active in the United States.
Key Developments
- In August 2023, Zenas BioPharma, published results from a Phase 2 investigation assessing obexelimab for the treatment of individuals with IgG4-Related Disease (IgG4-RD). Established on the outcomes of this investigation, a Phase 3 investigation in individuals with IgG4-RD is proceeding to additionally examine the effectiveness and safety of obexelimab administered as a subcutaneous injection.
- In March 2023, Pharmac, the Pharmaceutical Management Agency a New Zealand Crown entity began a planned on broadening sponsored access to rituximab (branded as Riximyo) for individuals with IgG4-related disease, a chronic inflammatory disorder.
Competitive Landscape
The major global players in the market include Pfizer Inc., AstraZeneca, Novartis AG, Zenas Biopharma, Amgen Inc., Bristol-Myers Squibb, Merck & Co., Inc., Sanofi S.A., Celltrion Healthcare Co., Ltd. and Cipla Inc. among others.
Why Purchase the Report?
- To visualize the global IgG4-related disease market segmentation based on drug class, disease type, route of administration, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of IgG4-related disease market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global IgG4-related disease market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
